A 72-year-old Japanese male with a history of colorectal cancer with metastases to the liver and peritoneum presented to the emergency department with fever and abdominal pain and was subsequently found to have Gram-negative bacteremia. The patient had undergone numerous chemotherapy treatment courses since his diagnosis 18 months prior as well as a central hepatectomy with hepaticojejunostomy. One year after the resection, he developed recurrent ascending cholangitis from a biliary stricture with an associated bile leak, necessitating the placement of a biliary stent and percutaneous drain. Despite drain placement, he presented to the hospital several times with Gram-negative bacteremia, most frequently growing either Escherichia coli or Klebsiella pneumoniae. Prior to transfer of his care to our institution 1 month prior, he had been placed on rotating prophylactic antibiotics, including amoxicillin-clavulanic acid, ciprofloxacin, and trimethoprim-sulfamethoxazole.
variicola in the database and the isolate was misidentified as K. pneumoniae. The microbiology laboratory personnel suggested that we explore the possibility that our isolate was K. variicola based on a recent report by Berry et al. on the misidentification of K. pneumoniae (1) .
Susceptibility testing revealed that the isolate was resistant to amoxicillin/clavulanic acid, cefazolin, ceftriaxone, ceftazidime, ciprofloxacin, gentamicin, and piperacillintazobactam and susceptible to amikacin, cefepime, tobramycin, and trimethoprimsulfamethoxazole. Subsequent blood cultures were negative. Since the isolate had a relatively resistant antibiotic profile, we attempted further species identification. DNA was extracted from the culture, and the KVAR_0717 gene of the Klebsiella species was PCR amplified and then subjected to Sanger sequencing. This gene is a target based on sequencing differences between K. variicola and K. pneumoniae (1) . Based on sequence homology determined using the Basic Local Alignment Search Tool (BLAST) (https:// blast.ncbi.nlm.nih.gov/Blast.cgi), the isolate was identified as K. variicola. The patient had his biliary drain repositioned and was ultimately discharged on cefepime for 2 weeks.
DISCUSSION
Conventional blood cultures can take 2 to 3 days to produce results, which has driven the development of advanced bacterial identification technologies that can decrease wait time by 24 to 36 h for a microbiologic diagnosis. These methods, however, are not infallible, and reporting misidentifications is imperative to the improvement of molecular diagnostic tools. Systems like Biofire, Vitek 2, Verigene, and MALDI-TOF MS can correctly identify Gram-negative organisms accurately a vast majority of the time, which is particularly helpful when resistance markers are detected. However, a percentage of isolates are still misidentified. Databases used in common molecular diagnostics platforms such as Verigene, Vitek, or MALDI-TOF MS remain incomplete, particularly with respect to rare bacterial species.
K. variicola is a nitrogen-fixing bacterium that was first identified in 2004 based on phylogenetic analysis of the rpoB gene sequence and DNA-DNA hybridization. It is estimated that 2.5% to 10% of K. pneumoniae isolates are actual misidentifications of K. variicola (1) (2) (3) (4) . K. variicola is likely under-recognized because of its similar phylogenetic and biochemical properties to those of K. pneumoniae. Until recently K. variicola and K. quasipneumoniae have not been included in common molecular databases, so they either were not identified or were misidentified. It is important to understand the limitations of molecular diagnostics and that correct identification is dependent on the databases available.
Misidentifications have been propagated over time because of the inclusion of misidentified K. variicola and K. quasipneumoniae sequences in American Type Culture Collection (ATCC) public gene sequence databases and in research studies. The inclusion of these gene sequences has conflated K. pneumoniae with K. variicola and K. quasipneumoniae until recently. The current Bruker MALDI-TOF MS microorganism database still does not include K. quasipneumoniae, leading to continued misidentification (4). K. variicola was recently added to the Bruker reference library, but prior to 2015 the reference library contained at least one strain of K. variicola that was misassigned as a K. pneumoniae strain (4).
Historically, K. pneumoniae was separated into three different phylogenetic groups based on sequencing of gyrA and parC genes. KpI is the largest cluster which includes K. pneumoniae subspecies; KPII and KPIII clusters include K. quasipneumoniae and K. variicola, respectively (2, 5, 6) . KPIII strains can be adonitol positive and have similar gyrA sequences.
It was once thought that adonitol testing could differentiate these clusters, but this has been disproven (2) . The inability to ferment adonitol can be a feature of K. variicola, but there can be variation in this test. Brisse et al. found that adonitol was positive in 4.3% of the KPIII isolates and Alves et al. showed that K. variicola was adonitol positive in about 20% of K. variicola isolates (6) . Although biochemical techniques can be suggestive, these tests are not absolute given the overlap that can occur (6, 7) . At this time the only definitive method to differentiate species is by whole-genome sequencing (WGS) or targeted sequencing.
Once we identified our original isolate as K. variicola, which was a first for our institution, we investigated other K. pneumoniae blood isolates that may have been misidentified. In 2017, there were a total of 56 K. pneumoniae blood isolates at our institution. Of the 56, there were 6, excluding the original isolate, that were not identified by Verigene but were later identified as K. pneumoniae on a Vitek MALDI-TOF MS. We were able to perform direct PCR and genetic sequencing on four of these isolates. Two of the four were identified as K. variicola, and the other two were more closely related to K. quasipneumoniae. In Fig. 1 all three K. variicola isolates are presented in the phylogenetic tree.
Overall, the genetic distances between all the Klebsiella strains were very close but not identical. For our three K. variicola strains, the first seven matches in the BLAST database had identity scores of Ͼ97%. The top matches included K. variicola strains At-22, DSM 15968, DX 120E, and GJ1-GJ3. There is a well-defined group with isolates 1 and 3, based on a high bootstrap value but not a value as high as that among the other clusters.
Based on the phylogenetic analysis, our K. variicola strains share the same ancestor as K. variicola strains GJ1, GJ2, and GJ3, which are carbapenem-resistant strains found to possess the bla NDM-9 gene (Fig. 1 ) though, notably, our isolate did not contain a carbapenemase. K. variicola strains GJ1, GJ3, and GJ3 have previously been identified as environmental strains isolated from the Gwangju tributary in South Korea (8) . Genomic sequencing of these isolates revealed that they carry the bla NDM-9 gene, a new variant of the New Delhi metallo-beta-lactamase gene, within the IncFII(y) plasmid. In addition to carbapenems, these isolates were also resistant to beta-lactams, sulfonamides, trimethoprim, aminoglycoside, fosfomycin, and fluoroquinolones (8) . The IncFII-type plasmid has also been involved with spreading the bla ctx-M-15 gene among Escherichia coli strains (8) . Other case reports have found K. variicola strains that produce K. pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase 1 (NMD-1) genes (4) . In this case series, due to an incomplete database, 2% of ESBL-producing K. pneumoniae isolates were misidentifications of K. variicola and K. quasipneumoniae, and 12.6% non-ESBL-producing K. pneumoniae isolates were misidentifications of K. quasipneumoniae (4). Our original isolate had a resistance profile similar to profiles of the strains from South Korea except that it was not carbapenem resistant. The other two K. variicola isolates from our institution had more favorable resistance patterns.
While management of this case was not affected by the misidentification, correct species identification carries important prognostic and epidemiologic implications. The importance of correctly identifying strains is emphasized by a study done in Sweden, which found an increased mortality in patients infected with K. variicola compared to that in patients infected with K. pneumoniae isolates although virulence factors could not be identified (9) . Though this study revealed a statistically significant difference in the mortality rates between the KPI and KPIII clades, the multivariate analysis was limited due to the small number of events that met the primary endpoint (30-day mortality).
In attempts to rectify the issue of misidentification, Garza-Ramos et al. developed a multiplex PCR to aid in correctly identifying K. variicola. They found K. variicola had a prevalence of 2.1% but that 56% of the isolates were multidrug resistant (3). This multiplex PCR provides the ability to differentiate between K. variicola and K. pneumoniae, which would be helpful in epidemiological and population studies. We did not use this multiplex PCR technique in our study and did not compare our method with the method of Garza-Ramos et al. as it was beyond the scope of our project, but we recognize that a more comprehensive approach such as whole-genome sequencing would provide greater genetic resolution of our isolate.
Continued efforts to understand K. variicola phylogenetic and genomic properties are needed to aid in understanding the prevalence, virulence, and resistance patterns of K. variicola. Misidentification can have significant clinical implications, especially given the unique resistance profiles of each organism. As new species are identified by DNA sequencing, molecular databases can be updated to facilitate more accurate identification. Updating the databases would allow us to understand an organism's epidemiology and the role that this could potentially play in the emergence of multidrug-resistant organisms, which may also affect the antibiotics reported on susceptibility panels. Further studies are needed to assess how these updates will impact actual clinical management. 
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